Overview
Lobbying Costs
250,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
UCB
EU Transparency Register
294359117093-66 First registered on 24 Apr 2015
Goals / Remit
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB).
Main EU files targeted
Engage governments and policymakers worldwide on issues important to UCB to:
• Ensure patients have access to medicines they need
• Provide coverage and reimbursement that reward innovation
• Introduce sound, science-based regulation
• Enable biotechnology research and development (R&D)Address
Head Office
Allée de la Recherche 60
Brussels 1070
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
1 FTE (50%)
1 FTE (25%)
People with less than 10% of their time spent on activities covered by the Register are not reportedPerson in charge of EU relations
Mr Xavier Hormaechea (Head of EU Corporate Affairs)
Person with legal responsibility
Mr Jean-Christophe Tellier (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
EFPIA = European Federation of Pharmaceutical Industries and Associations
(http://efpia.eu/)
EBE = European Biopharmaceuticals Entreprises (http://www.ebe-biopharma.eu/)Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
250,000€
EU grant income for closed financial year
59,890 € (Source: horizon2020 (Isotopics))
Other financial info
Funding from EU Institutions
Project : ISOTOPICS http://www.isotopics-project.eu/
Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occupancy are critically important approaches for de-risking drug innovation since they facilitate early identification of the candidates that display the best in vivo profile.
When successfully implemented, this strategy can accelerate the discovery of new therapeutic solutions to existing and emerging diseases, and enhance European pharmaceutical innovation.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
Meetings
Meetings
None declared